Drugs / 4-hydroxytamoxifen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04570956 | Jul 2021 → Oct 2024 | atypical lobular breast hyperplasia, lobular breast carcinoma in situ | Mayo Clinic | Terminated | No outcome recorded Stop: Business |
| Phase not applicable1 trial | ||||||
| — | NCT00084344 | Apr 2003 → Jul 2004 | breast cancer | Northwestern University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-05-19 | Senti Biosciences | Results Engineering a Gene Circuit-Enabled Cell Therapy with a Tamoxifen Regulated Safety Switch for Inducible Cell Death in Human Pluripotent Stem Cells and their Derivatives sentibio.com ↗
We designed a novel gene circuit which functions as a Safety Switch regulated by tamoxifen, an FDA approved drug with extensive clinical history and ability to cross the blood-brain-barrier. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-05-19 | Senti Biosciences | Engineering a Gene Circuit-Enabled Cell Therapy with a Tamoxifen Regulated Safety Switch for Inducible Cell Death in Human Pluripotent Stem Cells and their Derivatives sentibio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-hydroxytamoxifen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00084344 ↗ |
| Known as | 4-OHT | “Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day” NCT04570956 ↗ |
| Route | Topical | “Participants apply 4-hydroxytamoxifen gel in 4 metered doses daily to each breast” NCT00084344 ↗ |